IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1201.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 3-Dec-2016
The Lancet Oncology
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 3-Dec-2016
58th ASH Annual Meeting
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center.
NIH/National Cancer Institute, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Cancer Institute, Life Science Discovery Fund, Juno Therapeutics, Philanthropists

Contact: Sandy Van
svan2@fredhutch.org
808-526-1708
Fred Hutchinson Cancer Research Center

Public Release: 3-Dec-2016
58th ASH Annual Meeting
UH Rainbow Babies & Children's Hospital experts to present at ASH
Researchers from the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital will present data focused on improving clinical outcomes for pediatric hematologic disorders at the 58th Annual Meeting of the American Society of Hematology. The meeting, held from Dec. 3-6, 2016, in San Diego, Calif., gathers a global community of more than 20,000 hematologists to share education and research on the most pressing topics in hematology.

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Cleveland Medical Center

Public Release: 3-Dec-2016
58th ASH Annual Meeting
Research shows patients ineligible for studies may benefit from trial participation
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 3-Dec-2016
JAMA Oncology
Study estimates global cancer cases, deaths in 2015
In 2015, there were an estimated 17.5 million cancer cases around the globe and 8.7 million deaths, according to a new report from the Global Burden of Disease Cancer Collaboration published online by JAMA Oncology.

Contact: Kayla Albrecht, M.P.H.
albrek7@UW.EDU
206-897-3792
The JAMA Network Journals

Public Release: 2-Dec-2016
Journal of Nuclear Medicine
Novel anti-PSMA imaging agent quickly identifies prostate cancer lesions
New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of "The Journal of Nuclear Medicine," the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA (prostate-specific membrane antigen) minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.
ImaginAb Inc., Department of Defense Clinical Consortium, Memorial Sloan Kettering's Radiochemistry & Molecular Imaging Probe Core and Biostatistics Core

Contact: Laurie Callahan
lcallahan@snmmi.org
Society of Nuclear Medicine

Public Release: 2-Dec-2016
Modern Pathology
Johns Hopkins researchers uncover more genetic links to brain cancer cell growth
Two recently discovered genetic differences between brain cancer cells and normal tissue cells -- an altered gene and a snippet of noncoding genetic material -- could offer clues to tumor behavior and potential new targets for therapy, Johns Hopkins scientists report.
Childhood Brain Tumor Foundation, Pilocytic/Pilomyxoid Astrocytoma Fund, Lauren's First and Goal

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 2-Dec-2016
Lancet Oncology
Treatment significantly reduces chemotherapy-induced hearing loss in children
Investigators from Children's Hospital Los Angeles and 37 other Children's Oncology Group hospitals in the US and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing loss in children and adolescents with cancer. Results of this randomized, controlled, phase 3 study, called ACCL0431, have been published in the early online edition of Lancet Oncology.
Children's Oncology Group, NIH/National Cancer Institute

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles

Public Release: 1-Dec-2016
JAMA Oncology
Study examines association of asbestos exposure, mesothelioma in Eastern China
A new research letter published online by JAMA Oncology looks at asbestos exposure and malignant mesothelioma in Eastern China.

Contact: Nana Ohkawa
nohkawa@cc.hawaii.edu
The JAMA Network Journals

Public Release: 1-Dec-2016
Nature Communications
Protective barrier inside chromosomes helps to keep cells healthy
Fresh insights into the structures that contain our genetic material could explain how the body's cells stay healthy.
Wellcome Trust

Contact: Corin Campbell
Corin.Campbell@ed.ac.uk
44-131-650-6382
University of Edinburgh

Public Release: 1-Dec-2016
Scientific Reports
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against colorectal cancer.

Contact: Saori Obayashi
saori_obayashi@mail.osaka-u.ac.jp
81-661-055-886
Osaka University

Public Release: 1-Dec-2016
Cancer Letters
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
IDIBELL researchers describe the Ewing's sarcoma (ES) methylation profile for the first time. The methylation profile unveils the potential of the PTRF gene as a prognostic marker of the disease. The reestablishment of PTRF expression could serve as a therapeutic option in the future.
Carlos III Institute of Health, Asociación Española contra el Cáncer, Fundación Alba Pérez

Contact: Gemma Fornons
gfornons@idibell.cat
0034-638-685-074
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 1-Dec-2016
28th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"
Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective.
Genentech

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 1-Dec-2016
Cancer Epidemiology, Biomarkers & Prevention
Alcohol intake associated with increased risk of melanoma
Alcohol intake was associated with higher rates of invasive melanoma among white men and women. White wine carried the most significant association, and the increased risk was greater for parts of the body that receive less sun exposure.
National Institutes of Health

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 1-Dec-2016
Cell
Study reveals new role for Hippo pathway in suppressing cancer immunity
Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings could have a clinical role in improving efficiency of immunotherapy drugs.
National Institutes of Health, Whitworth Immunotherapy Foundation

Contact: Yadira Galindo
ygalindo@ucsd.edu
858-249-0456
University of California - San Diego

Public Release: 1-Dec-2016
JAMA
Proposed biosimilar drug shows potential as breast cancer treatment
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.

Contact: Elizabeth Fernandez
Elizabeth.Fernandez@UCSF.edu
The JAMA Network Journals

Public Release: 1-Dec-2016
Public Health Nursing
Recovering Latina breast cancer patients report big gaps in 'survivorship' care
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment.
California Breast Cancer Research Program

Contact: Carolyn Mendez-Luck
Carolyn.Mendez-Luck@oregonstate.edu
541-737-4503
Oregon State University

Public Release: 1-Dec-2016
Journal of Thoracic Oncology
In cancer immunotherapy, one PD-L1 test to rule them all?
Ambitious collaboration between industry, advocacy and academia results in study comparing leading four assays for anti-PD-L1 immunotherapies.
Federal Drug Administration, American Association for Cancer Research, American Society for Clinical Oncology

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 1-Dec-2016
Journal of Biomedical Nanotechnology
UTSA study describes new minimally invasive device to treat cancer and other illnesses
A new study by Lyle Hood, assistant professor of mechanical engineering at The University of Texas at San Antonio (UTSA), describes a new device that could revolutionize the delivery of medicine to treat cancer as well as a host of other diseases and ailments. Hood developed the device in partnership with Alessandro Grattoni, chair of the Department of Nanomedicine at Houston Methodist Research Institute.

Contact: Joanna Carver
joanna.carver@utsa.edu
210-243-4557
University of Texas at San Antonio

Public Release: 1-Dec-2016
Nature Communications
Study: Enhancing cancer response to radiation
Study provides early evidence that a panel of microRNA may be used in the future as a biomarker for several types of cancer.
NIH/National Heart Lung Blood Institute, OHSU Knight Cancer Institute

Contact: Amanda Gibbs
gibbam@ohsu.edu
503-494-5640
Oregon Health & Science University

Public Release: 1-Dec-2016
Scientific Reports
URI scientist: Rare childhood disease linked to major cancer gene
A team of researchers led by a University of Rhode Island scientist has discovered an important molecular link between a rare childhood genetic disease, Fanconi anemia, and a major cancer gene called PTEN. The discovery improves the understanding of the molecular basis of Fanconi anemia and could lead to improved treatment outcomes for some cancer patients.

Contact: Todd McLeish
tmcleish@uri.edu
401-602-0896
University of Rhode Island

Public Release: 1-Dec-2016
Cell
Disabling critical 'node' revs up attack when cancer immunotherapies fall short
An existing drug known as a JAK inhibitor may help patients who don't respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance.
Melanoma Research Alliance, Parker Institute for Cancer Immunotherapy, Robertson Foundation/Cancer Research Institute Irvington Fellowship, the National Institutes of Health, NIH/National Cancer Institute, Basser Research Center for BRCA, and others

Contact: John Infanti
john.infanti@uphs.upenn.edu
215-349-5660
University of Pennsylvania School of Medicine

Public Release: 1-Dec-2016
Supportive Care in Cancer
Four weeks to prepare cancer patients for surgery
Just four weeks of prehabilitation may be enough to help some cancer patients get in shape for surgery. That's according to a recent study of close to 120 colorectal cancer patients in Montreal. This potentially means that, barring unforeseen circumstances that stem from the surgery itself, their recovery is likely to be speedier too, according to earlier research from the same McGill-led team.

Contact: Katherine Gombay
katherine.gombay@mcgill.ca
514-398-2189
McGill University

Public Release: 1-Dec-2016
58th ASH Annual Meeting
None
The latest advances in the study of blood diseases presented at annual meeting of ASH
The 2016 American Society of Hematology Annual Meeting highlights research from St. Jude Children's Research Hospital scientists and clinicians.

Contact: Barry Whyte
barry.whyte@stjude.org
901-201-7646
St. Jude Children's Research Hospital

Public Release: 1-Dec-2016
58th ASH Annual Meeting
With promising results from emerging therapies, Penn research yields hope for amyloidosis
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania.
Academic Myeloma Consortium, Prothena Biosciences

Contact: John Infanti
john.infanti@uphs.upenn.edu
215-349-5660
University of Pennsylvania School of Medicine

Showing releases 1-25 out of 1201.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!